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Abstract 
 
Off-label and unlicensed drug use in neonatology: reality in a Portuguese university 
hospital 
Introduction: This study aims to characterize the drugs used in a Portuguese Neonatal 
Intensive Unit Care (NICU), assess the rate of off-label or unlicensed drugs use 
according to the information available in the Summary of Product Characteristics (SPC) 
and compare results between preterm and full-term neonates. 
Material and methods: A 6-month period retrospective cross-sectional study was 
conducted in our NICU in 2013. Prescribed drugs data were recorded and compared 
with the paediatric information contained in drugs SPC. 
Results: We analyzed 1011 prescriptions of 84 active substances, made in 218 
admissions. In 42.9% of the cases, medicines were used according to SPC 
information; 27.9% of drugs were approved for neonatal period but used in an off-label 
manner; off-label drugs for neonates were used in 10.1%, whereas those with 
undetermined approval state and contraindicated were used 6.0% and 8.7% of the 
cases, respectively. Unlicensed prescriptions accounted for 4.4% of total. Preterm 
received a higher rate of drugs used according to SPC (p<0.0001), whereas full-term 
received more off-label drugs for dose/frequency (p<0.0001) and contra-indicated for 
neonates (p<0.012).  
Discussion: Preterm neonates received a higher median number of drugs, since they 
stayed longer in the unit. The main reason for off-label prescribing was the use of 
doses/frequencies of administration different from those stated in SPC, suggesting that 
updating these documents is necessary. Manipulation of medicines is one of the 
causes for unlicensed drugs use, emphasizing the lack of appropriate formulations for 
neonatal age. 
Conclusion: Progresses have been made to reduce the risks of off-label/unlicensed 
prescriptions, but competent authorities must continue their efforts to develop safer and 
more effective drugs for neonatal period.  
Keywords: Intensive Care Units, Neonatal; Off-Label Use; Drug Labeling; Drug 
Therapy; Infant, Newborn. 
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Resumo 
Uso de fármacos off-label e não licenciados em neonatologia: realidade de um hospital 
universitário português 
Introdução: Este estudo pretende caracterizar os medicamentos usados numa 
Unidade de Cuidados Intensivos Neonatais (UCIN) portuguesa, avaliar a frequência do 
uso de fármacos off-label ou não licenciados de acordo com a informação disponível 
no Resumo das Caraterísticas do Medicamento (RCM) e comparar resultados entre 
recém-nascidos prematuros e de termo. 
Materiais e Métodos: Um estudo retrospetivo transversal foi conduzido na nossa UCIN 
no primeiro semestre de 2013. Os dados das prescrições realizadas foram 
comparados com a informação pediátrica contida nos RCMs. 
Resultados: Analisámos 1011 prescrições respeitantes a 84 substâncias ativas, feitas 
em 218 admissões. Em 42.9% dos casos, os fármacos foram usados de acordo com a 
informação do RCM; 27.9% dos fármacos eram aprovados para o período neonatal 
mas usados de forma off-label; medicamentos off-label para a idade neonatal foram 
usados em 10.1%, enquanto aqueles com estado de aprovação indeterminado ou 
contraindicados foram usados em 6.0% e 8.7% dos casos, respetivamente. As 
prescrições não licenciadas representaram 4.4% do total. Os recém-nascidos pré-
termo receberam uma taxa superior de fármacos usados de acordo com o RCM 
(p<0.0001), enquanto os de termo receberam mais fármacos off-label para 
dose/frequência (p<0.0001)  e contraindicados para recém-nascidos (p<0.012).  
Discussão: Os prematuros receberam um número mediano de fármacos superior, o 
que se relaciona com o seu internamento mais prolongado. A principal razão para 
prescrições off-label foi a utilização de doses/frequências de administração diferentes 
das referidas no RCM, reforçando a necessidade de atualização destes documentos. 
A manipulação dos medicamentos é uma das causas para o seu uso não licenciado, 
enfatizando a falta de formulações apropriadas à idade neonatal. 
Conclusão: Têm sido feitos progressos para reduzir os riscos destas prescrições off-
label/não licenciadas, mas esforços para o desenvolvimento de medicamentos mais 
seguros e eficazes para este período devem continuar a ser envidados. 
Palavras-chave: Unidades de Cuidados Intensivos Neonatais; Resumo das 
Características do Medicamento; Uso Off-Label; Farmacoterapia; Recém-nascido. 
 Off-label and unlicensed drug use in neonatology: reality in a Portuguese university hospital Dissertação no âmbito do Mestrado Integrado em Medicina, de Joana Raquel Brandão da Silva 
 
Introduction 
 
Global policies for prescribing medicines for children have been changed since it was 
established between the international medical community the need of therapeutical 
measures adapted to this particular stage of life.1  
There are two distinct entities when referring to non-labelled prescriptions: off-label and 
unlicensed uses. Off-label relates to medication use beyond the conditions of the 
registered product as specified in the Summary of Product Characteristics (SPC) in 
terms of patient age, indication, dosage, frequency and route of administration. 
Unlicensed refers to a drug that has not a Marketing Authorization (MA), is not licensed 
in a country, or does not have an appropriate formulation available in the market.2,3 
Besides the legality or adequate justification for the use of unlicensed/off-label drugs, it 
brings ethical dilemmas and can be associated with clinical and safety issues.4-7  
Many studies have shown that neonates have higher risk of using off-label drugs than 
the children of other age groups.6,8-11 A range from 55 to 88% in the use of unlicensed 
or off-label drugs at neonatal settings is referred in literature reviews on this theme; the 
proportion of patients receiving at least one of these drugs ranges from 80-97%.5,6,11  
Other specificities of neonatology are the added risk of preterm newborns to die or 
develop serious morbidity throughout life.9,12 For this reason, just like sick full-term 
newborns are more exposed to the off-label/unlicensed medications, the most 
premature and low birth weight neonates receive the greatest number of drugs.13-15 
Moreover, there are also the specific pharmacokinetics and the fast body mass and 
composition change of newborns, making them particularly susceptible to the risks of 
developing adverse drug reactions (ADRs) or experiencing errors in adjusting doses or 
formulations.5,6,9,10  
In 2010, European Medicines Agency (EMA) published a report that describes existing 
data on paediatric uses of medicinal products by country. Portuguese data were 
collected in 22 hospitals referring to inpatients only; off-label status related information 
was available in 33% of the cases, but there was no quantitative measure of the extent 
of medicines used in paediatric population.16  
Our study proposes (1) to assess the extent and type of drugs used in our Neonatal 
Intensive Care Unit (NICU), (2) analyze the frequency of off-label/unlicensed 
prescriptions according to information available on drugs SPC, and (3) compare results 
between preterm and full-term neonates. 
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Material and Methods 
 
This is a retrospective cross-sectional study, performed at a Portuguese NICU, located 
at one of the university hospitals that provide tertiary level treatment. This unit of 
reference has 17 beds, where 445 babies were treated in 2013. 
All clinical information and medicines prescribed to neonates (0-27 days of postnatal 
age, corrected for a gestational age of 40 weeks in case of preterm neonates) admitted 
in the neonatal unit during a 6-month period (between January 1st and June 30th, 2013) 
were recorded in an electronic database, after review the patients’ medical records. 
Informations registered include demographic data (gender, gestational age, type of 
delivery, birthweight, Apgar score at first and fifth minutes), clinical information 
(diagnoses, length of stay, place to where the newborn was discharged) and 
prescribed drugs data (active substance, codification according to the Anatomical 
Therapeutic Chemical (ATC) classification system17, indication, dosage, frequency, 
route of administration and the occurrence of ADRs).  
Most prescriptions were based on active substance, so we consulted the SPC from the 
trademarks provided by hospital pharmacy during this period, available in the database 
of medicinal products for human use of INFARMED, the regulatory authority of 
medicines in Portugal.18 In case of missing or ambiguous information regarding the use 
in neonates, other SPCs of the same active substance but different trademark were 
analyzed and it was considered the one with more extensive data about paediatric use. 
Oxygen therapy, intravenous replacement solutions and electrolyte support, flushes for 
intravenous lines, drugs used during surgeries, enteral and parenteral nutrition, 
contrast agents, vaccines of Portuguese National Vaccination Programme, blood 
products (except albumin and immunoglobulins), basic creams, drugs on clinical trials 
or phototherapy were excluded. 
As shown in Fig.1, drugs without MA or manipulated in the hospital pharmacy were 
classified as unlicensed, while the remaining were considered licensed and 
subsequently classified into approved, off-label, contraindicated or with undetermined 
state of approval for neonatal period. We also evaluated if the approved drugs for 
neonatal use were utilized in an off-label manner regarding to gestational or postnatal 
age, indication, route of administration, dose and/or frequency, and these categories 
may coexist. 
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Data collection and statistical analysis were performed with IBM SPSS Statistics v.21®. 
Continuous variables were characterized by mean (± standard deviation) and median 
(minimum-maximum) depending on they had symmetric or asymmetric distribution, 
respectively, and categorical variables by absolute and relative frequencies. To 
compare continuous variables we used parametric (independent t test) or non-
parametric (Mann-Whitney U test) tests if they had symmetric or asymmetric 
distribution, respectively. Categorical variables were compared by Chi-squared or 
Fisher’s exact test. A p value less than 0.05 was considered statistically significant. 
The protocol was approved by the Ethical Committee and Administrative Council of the 
institution. 
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Results 
 
 
Population 
A total of 218 admissions were comprised, as shown in Table 1. From the total 
patients, 55.5% were males. Their mean gestational age and birthweight were 
36.07±4.0 (SD) weeks and 2554±910.5 (SD) grams, respectively, with statistically 
significant differences between preterm and full-term neonates (p<0.001). 
Caesarean sections were performed in 55% of deliveries, with a higher rate in preterm 
neonates; the vaginal and forceps/vacuum deliveries were more frequent in full-term 
neonates (p<0.023). 
At admission, 165 neonates (75.7 %) had a medical health condition, whereas 32 
(14.7%) had a surgical condition and 21 (9.6%) had a cardiac one. 
We categorized all diagnoses in the following categories, in descending order of 
frequency (n value; %): metabolic (94; 27.6%), cardiovascular (48; 14.1%), respiratory 
(41; 12.1%), neurologic/ sense organs (33; 9.7%), hematologic (32; 9.4%), digestive 
(28; 8.2%), infectious (25; 7.4%), nephro-urologic (23; 6.8%), and others (16; 4.7%). 
In 54 cases (24.8%) oxygen was administered, and 81 neonates (37.2%) were in 
mechanical ventilation. Eighty newborns (36.7%) had venous and/or arterial catheters, 
and 95 newborns (43.6%) required total parenteral nutrition for a period. 
Median length of stay were 9 days to preterm and 6 days to full-term neonates 
(p<0.001). At the time of discharge, 96.3% of these were alive; full-term neonates were 
more discharged to home and less discharged to other hospitals than preterm 
neonates (p<0.001). 
 
Drug prescriptions 
A total of 1011 prescriptions were made, concerning to 84 different active substances 
(Table 2). The median number of drugs needed to each newborn was 3 (p<0.001). The 
maximum number of medicines used in preterm and full-term population was 34 and 22 
per patient, respectively (Table 1); 69.7% of patients received at least one off -
label/unlicensed drug (72.3% in preterm and 67.7% in full-term neonates).  In 30 cases 
(13.8%), all of them with a gestational age ≥35 weeks, the patients did not receive any 
drug. 
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As shown in Fig. 2, the drugs most used were anti-infectives for systemic use (31.9%), 
followed by those which act at nervous system (18.4%), alimentary tract (14.7%), 
cardiovascular system (12.3%), and blood forming organs (7.3%).  
The top 10 administered drugs were gentamicin (n=104), ampicillin (n=94), 
cholecalciferol (n=60), morphine (n=49), paracetamol (n=43), caffeine citrate (n=40), 
multivitamins (n=38), clotrimazole (n=35) furosemide (n=32), and iron hydroxide 
polymaltose (n=30).  
The percentage of prescriptions of approved drugs for neonatal period was 70.8%, but 
only 42.9% of total were used according to SPCs information (p<0.0001). In 25.7% of 
the cases, the drugs were off-label for dose and/or frequency (p<0.0001) and 1.4% 
were simultaneously off-label for gestational age and dose (p<0.001). The remaining 
prescriptions (29.2%) were non-labelled for this age group: 10.1% were off-label, 8.7% 
were considered contraindicated (p<0.012), 6% had undetermined state of approval for 
neonates, and 4.4% were unlicensed, as shown in Table 3.  
The intravenous route was the most applied, in 61.4% of the cases (p<0.0001). As can 
been seen in Table 4, it was followed by oral route in 21.5% of prescriptions (p<0.003).  
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Discussion 
 
Prescription in neonatal setting 
To our knowledge, this is the first study involving medical prescriptions in a Portuguese 
NICU. Our study population represents the typical one of a specialised NICU, 
consisting of a high rate of patients transferred from other hospitals (26.1%) and a 
median length of stay of seven days. In other NICU’s, median values reported were 
superior (11-15 days).12,13,19 The transfers to other hospitals done in 19.7% of the 
cases, mainly in preterm neonates, could explain these differences. As we can verify in 
Table 1, preterm neonates had a longer stay (median of 9 days), which is consistent 
with high rates of medical complications needing prolonged NICU stays.15 Each 
newborn was exposed to a median of three different drugs. Two recent studies 
performed in NICUs with similar prevalence of off-label/unlicensed drugs use reported 
an equal median,20,21 whereas others refer median from 4 to 8 drugs per patient.12,13,19 
With regard to the higher number of drugs necessary in preterm neonates (median=4), 
it confirms the current knowledge that younger, lighter and most vulnerable newborns 
receive more drugs than the more matures.13-15  
Beyond the classical division into off-label and unlicensed drugs, we chose to add 
“undetermined state approval” and “contraindicated” categories, in order to be more 
precise in data analysis. However, typically they are included in off-label category by 
other authors.12,14  
In order to compare our results with international reality, we will consider the 
designation off-label in a broader sense, as concerning to a use not recorded in the 
SPC for a drug approved in Portugal. Thereby, the sum of drugs used in off -label 
manner to neonatal period, gestational age, indication, dose/frequency and  route of 
administration, together with those with undetermined approval state and 
contraindicated, results in a total of 52.7% off-label prescriptions (47.0% in preterm and 
60.9% in full-term neonates), as shown in Table 3. This frequency is similar to those 
described in recent studies (46.5%-65%),21-24 but is superior to some researches that 
report  rates of 15.5%7, 27.7%14 and 29.5%19.  
In studies where off-label/unlicensed prescriptions are presented together, prevalence 
rates range from 34% to 69%.10,12,14,19,20,23-25 Comparing to our results, if we add the 
use of unlicensed to off-label drugs, a rate of 57.1% off-label/unlicensed prescriptions 
is obtained, according to SPCs information.  
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The wide range of results detected between our study and others mentioned above 
may be due to differences in the definitions of off-label use, licensing practices/policies 
in different countries, and the type of hospital where the study is performed.13 The 
reviews that show rates of 55-80% of off-label/unlicensed drugs, describe studies 
conducted years ago; meanwhile, drug labelling for some drugs have been 
amended.6,11 
We identified 84 active substances used, all listed in Table 2 according to their 
application and SPCs information. The number of products identified varies greatly 
between the studies, depending on the period and number of units included; it ranges 
from 24 drugs in a 4-month study in a single unit to 93 in a 24-hours evaluation in 17 
NICUs.19-21,24  
Like in other studies, anti-infectives for systemic use and drugs for central nervous 
system were the most prescribed (Fig.2).12 
 
 
Approved drugs in neonatal period 
Limiting the discussion to drugs approved for neonatal age, a statistically significant 
difference in the use of drugs according to the SPC was verified, with almost half of 
drugs utilized in preterm neonates following SPCs advices (Table 3). In fact, some 
drugs employed in prematurity are so specific that studies were performed to define 
doses and get authorization; some of them, like ibuprofen for patent ductus arteriosus 
and caffeine citrate for apnoea of prematurity, are even orphan drugs. 
In several studies, the main reason for off-label classification was the lack of paediatric 
information, especially for neonates.10,20 In others, off-label use was assigned to 
different doses and dosing frequencies from those recommended in product 
licenses.3,11,23 The latter is the main reason that led us to classify an approved drug as 
off-label too, which occurred in 33.5% of the cases in full-term and 20.3% in preterm 
neonates (p<0.001). 
Most drugs used in a dose and/or frequency different from those stated in SPC are 
anti-infectives for systemic use. Ampicillin and gentamicin were the most prescribed 
antibiotics, once the empirical therapy for newborns should be based on a combination 
of ampicillin and an aminoglycoside.26 Their labels contain information concerning to 
variable doses according to weight and postnatal age, respectively, but do not consider 
the variations in pharmacokinetics that occurs with the gestational age at birth time. 
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Gentamicin was also used in a single daily dosing, although SPC solely describes 
divided doses. The medical prescription in our ward is supported several times by 
paediatric handbooks and scientific papers, reason why we consulted LexiComp’s 
Pediatric & Neonatal Dosage Handbook. This publication takes into account the 
gestational age and weight, so these anti-infective prescriptions would not be off-label if 
we considered only the book.27 A survey on off-label antibiotic use performed in three 
European countries describes an unregistered dose use in a range of 37.8% to 51.7% 
of prescriptions in NICU, so our findings are in line with European reality.26  
There were also statistically significant differences in the use of off-label drugs for 
gestational age and dose, since it was in preterm infants that these drugs were 
administered in these conditions. To exemplify, intravenous paracetamol SPC refers 
that “data on safety and efficacy are not available for preterm newborns”, although the 
oral paracetamol SPC does not mention the absence of this data and displays dosage 
for infants weighing less than 4000 g, regardless of gestational age.  
 
 
Off-label prescribing for neonatal period 
In 10.1% of the prescriptions, SPCs of corresponding drugs establish a minimum age 
limit from which their use is approved: budesonide can be used in children over 2 years 
of age, while adenosine efficacy and safety in children aged between 0 and 18 years 
has not been established (Table 3). Not all drugs classified in Table 2 as off-label for 
neonatal period are due to age group. For example, sodium bicarbonate was 
prescribed in a concentration of 8.4%, but its SPC recommends the administration of a 
concentration of 4.2% in children younger than 2 years.  
Ranitidine and domperidone, belonging to the third ATC category most used in our 
population, are useful examples to demonstrate other findings. According to SPC, the 
safety of using ranitine in children under 12 years is not fully elucidated. In an attempt 
to clarify the authorised age group for this drug, we consulted the assessment of needs 
of gastroenterological drugs for paediatric age published in 2006, and no age limit is 
mentionated in France, but in Germany it is approved for children older than 6 years.28  
We consulted LexiComp’s Handbook too, noticing that it has information on ranitidine 
neonatal dosing.27 The recommended dosage in domperidone SPC comprises only 
children over 2 years; however, in the already referred EMA’s document, domperidone 
is considered to be already covered and that there is no need for further paediatric 
data;28 in LexiComp’s handbook, it is not even mentioned27. Thus, we can conclude 
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that the information conveyed by different authorities is unequal and requires an 
increased effort in decision-making by paediatricians.  
During our approach, other SPCs of the same active substances were read and we 
found lack of updated information about neonatology use in some of them. For 
example, SPC of ampicillin trademark supplied by hospital pharmacy is silent on 
neonatal use or posology, but other trademark SPC exposes information about it. This 
would result in a possible categorization of off label drug to neonatal period, only 
because the label is not updated. As mentioned in other works, including one 
performed in Portugal, many of the drugs used in this period are in the market for 
several years. Nevertheless, the SPCs were not updated, although there is a long 
clinical experience in their use.4,29  
We also verified that in 6.0% of prescriptions, the SPCs consulted have no specific 
information on the use of the drug in paediatric population, so prescriptions were 
classified as “undetermined state of approval” (Table 3). They present ambiguous 
information, like “should be administered with caution in children” stated in 
dexamethasone SPC. However, it is a lower percentage when compared with the 
22.7% of drugs referred in an Italian study as containing no information for paediatric 
use.24  
 
 
Contraindicated drugs 
As presented in Table 3, 8.7% of all prescriptions in the NICU were contraindicated 
drugs administered in a statistically significant higher proportion in preterm neonates 
(4.7%). This percentage is much higher than observed in other studies; in one of them, 
authors reported a rate of 0.3% of contraindicated drugs use in neonates.30 
Morphine was the most frequently contraindicated drug used, once it’s SPC states 
dosage for children over 1 year and contraindication for newborns, as they present 
increased sensitivity to opioids and consequently greater depression of respiratory 
center. Indeed, it was been identified by EMA as authorized to infants over 6 months, 
but it is still necessary data on pharmacokinetics, safety and efficacy in younger 
children.28 However, there are recommended doses for this age group and its 
management is done in intensive care, minimizing the risks of respiratory depression.27  
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Unlicensed prescribing 
In 4.4% of the prescriptions, drugs were classified as unlicensed, for three main 
reasons: some active substances, like trimethoprim and hydrochlorothiazide, are 
currently marketed only in combination with other active substances; some drugs are 
no longer available in the market, like chloral hydrate; and, at last, drugs like 
propranolol and spironolactone are not marketed in formulations suitable for neonatal 
age (Table 3). The oral formulations are available only in tablets or capsules, so their 
manipulation in the hospital pharmacy is required in order to be possible to babies 
swallow the medicine.29 Of unlicensed drugs shown in Table 4, almost all are 
mentioned in the list of manipulated medicines, which are reimbursed, published in 
Republic Diary in 2010 (except acetylsalicylic acid and calcium carbonate), 
demonstrating that knowledge of the existence of gaps in the medicines prepared 
industrially is not recent.31 Such manipulated formulations have poor information 
regarding bioavailability and stability, so the only way to overcome a potential 
unnecessary risk of their administration in neonates would be the investment of 
pharmaceutical companies in new oral formulations in spite of the small paediatric 
market.2,20,29,32 However, appropriate formulations do not obviate the need for more 
studies on safety and efficacy directed to these active substances, since available 
SPCs of these drugs do not contain satisfactory information for paediatric age. The 
absence of SPCs, as in the case of chloral hydrate, would leave doctors without 
documentary support for its therapeutic choice, if there were no reference books. This 
failure could justify the findings of a recent study that related medication errors and 
medicines license status, in which unlicensed drugs use appears to be associated with 
medication errors in neonates and children.22,33  
 
 
Route of administration 
The evaluation of the administration routes showed significant differences between the 
two population groups (Table 4). Intravenous route was the most utilized (61.4% of 
total), being even more apparent this trend in full term neonates who received 70.6% of 
drugs by this route. Oral route was used in 21.5% of the cases, mainly in preterm 
neonates (p<0.003). This is an unexpected result, since their immaturity when 
compared with the full-term would lead to suppose that oral route was more used in 
latter. In other study the results are dissimilar, with enteral route being the most used 
(49% of cases), followed by parenteral one (46%)13.  
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The remaining statistically differences were verified in drugs administered by 
endotracheal and subcutaneous routes, used mainly in preterm neonates due to the 
drugs characteristics. They used poractant alpha, a surfactant to endotracheobronchial 
instillation utilized in the treatment or prophylaxis of respiratory distress syndrome in 
newborns; likewise, epoetin beta, a drug approved for the prevention of anaemia of 
prematurity, was the only one administered subcutaneously.  
 
 
Adverse drug reactions 
In contrast with one of the first studies that evaluated ADRs in neonates, which found a 
rate of 6% of ADRs in a population similar to ours (where was used off-label and/or 
unlicensed in 55% of the cases),6 no ADRs to the drugs comprised in this study were 
reported to the competent authorities on pharmacovigilance during the study time. The 
retrospective design of the study may have overlooked adverse reactions reported in 
clinical notes or under-reporting of possible ADRs may have occurred, as the non-
occurrence or failure to identify ADRs may be explanations for this finding.10 
We also observed that several drugs were given for each newborn, with a maximum 
number of 34 and 22 for preterm and full-term neonates, respectively. In fact, 
polypharmacotherapy is a common practice in NICUs (especially in high-risk neonates) 
and is associated with a statistically significant superior risk of developing ADRs; this 
risk is also associated with a greater use of unlicensed/off-label medicines.32 There is 
lack of information on the compatibility of these drugs, particularly with regard to 
intravenous drug co-infusions; in fact, only 4% of intravenous co-infusions were shown 
to be compatible without restrictions in a NICU, raising the risk of serious drug 
interactions.5 
 
 
Impact of European legislation 
Portugal follows the European Union Regulation On Medicinal Products for Paediatric 
Use (Regulation nº 1901/2006) implemented in 2007.34 After more than six years in 
force, EMA published a report on experience acquired with the application of this 
regulation which implemented a system of obligations, incentives and rewards to the 
development of drugs for paediatric age in European Member States.35 The document 
refers 600 Paediatric Investigation Plans agreed by the end of 2012, most of them for 
 Off-label and unlicensed drug use in neonatology: reality in a Portuguese university hospital Dissertação no âmbito do Mestrado Integrado em Medicina, de Joana Raquel Brandão da Silva 
 
medicines that were not authorized in EU and the remaining related to new indications 
for patent-protected products or paediatric-use marketing authorizations. However, only 
2% of these were exclusively addressed to neonatal intensive care.36  
The number of paediatric clinical trials remained stable between 2006 and 2012 but 
there was an evident increase in the number of paediatric study participants, in 
particular for the age group of 0 to 23 months, who were normally not included in trials 
prior to 2008. Regarding to information on medicines used in children, more than 
18000 study reports were submitted to EMA since 2008, but it originated only 65 actual 
changes to authorized SPCs of products.36 
These results are encouraging, but there is still a long process until we reach 
satisfactory and ideal paediatric pharmacological treatments. 
 
 
Limitations of this study 
The results reflect the reality of a single tertiary care unit, inserted in an academic 
hospital, so they may reflect only our local reality and not the current practice in centers 
throughout the country. 
We did not assess the outcomes of medication use, so we can not argue about the real 
risks versus benefits of their use.  
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Conclusions 
 
Off-label prescription is a frequent practice in this Portuguese NICU, performed in 
52.7% of the cases, mainly by the use of different doses and/or frequency from those 
stated in drugs’ SPCs. These results give more strength to the need of update SPCs 
information in case of medicines whose use experience is long. Paediatric studies 
should be conducted on drugs intended to be introduced in the market too, with the aim 
of reducing the rate of off-label administrations in the future, providing safe and 
adequate medication to neonatal patients. Unlicensed drugs use was more modest 
(4.4%), but reinforce the need for pharmaceutical companies to invest in new paediatric 
formulations.  Great progresses have been made to reduce the inherent risks of these 
prescriptions, but it is crucial that paediatric and neonatal societies, government 
organizations and pharmaceutical companies join forces to achieve the approval of a 
larger number of innovative and beneficial medicines for in children.  
 
 
 
 
 Declaration of interest 
 
The authors state no conflict of interests and have received no payment to perform this 
work. 
 
 
 
 Acknowledgements 
 
We would like to thank Dr. Teresa Soares, from the Hospital Pharmacy, for clarifying 
the drugs trademarks used in our NICU.  
 Off-label and unlicensed drug use in neonatology: reality in a Portuguese university hospital Dissertação no âmbito do Mestrado Integrado em Medicina, de Joana Raquel Brandão da Silva 
 
References 
 
1. Lenk C. Off-label drug use in paediatrics: a world-wide problem. Curr Drug 
Targets. 2012;13:878-84. 
2. Zingg W, Posfay-Barbe KM. Antibiotic use in children - off-label use. Curr Drug 
Targets. 2012;13:885-92. 
3. Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, 
Kokki H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland 
and review of the international literature. J Clin Pharm Ther. 2009;34:277-87. 
4. Ribeiro M, Jorge A, Macedo AF. Off-label drug prescribing in a Portuguese 
paediatric emergency unit. Int J Clin Pharm. 2013;35:30-6. 
5. Fabiano V, Mameli C, Zuccotti GV. Adverse drug reactions in newborns, infants 
and toddlers: pediatric pharmacovigilance between present and future. Expert Opin 
Drug Saf. 2012;11:95-105. 
6. Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns 
and children in different settings: a review of the literature and a consideration about 
drug safety. Expert Opin Drug Saf. 2006;5:703-18. 
7. Palcevski G, Skocibusic N, Vlahovic-Palcevski V. Unlicensed and off-label drug 
use in hospitalized children in Croatia: a cross-sectional survey. Eur J Clin Pharmacol. 
2012;68:1073-7. 
8. Zhang L, Li Y, Liu Y, Zeng L, Hu D, Huang L, et al. Pediatric off-label drug use 
in China: risk factors and management strategies. J Evid Based Med. 2013;6:4-18. 
9. Jacqz-Aigrain E. Drug policy in Europe Research and funding in neonates: 
current challenges, future perspectives, new opportunities. Early Hum Dev. 
2011;87:S27-30. 
10. Kimland E, Nydert P, Odlind V, Bottiger Y, Lindemalm S. Paediatric drug use 
with focus on off-label prescriptions at Swedish hospitals - a nationwide study. Acta 
Paediatr. 2012;101:772-8. 
11. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur 
J Pediatr. 2005;164:552-8. 
12. Neubert A, Lukas K, Leis T, Dormann H, Brune K, Rascher W. Drug utilisation 
on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based 
analysis. Eur J Clin Pharmacol. 2010;66:87-95. 
13. Kumar P, Walker JK, Hurt KM, Bennett KM, Grosshans N, Fotis MA. Medication 
use in the neonatal intensive care unit: current patterns and off-label use of parenteral 
medications. J Pediatr. 2008;152:412-5. 
14. Carvalho CG, Ribeiro MR, Bonilha MM, Fernandes M, Jr., Procianoy RS, 
Silveira RC. Use of off-label and unlicensed drugs in the neonatal intensive care unit 
and its association with severity scores. J Pediatr (Rio J). 2012;88:465-70. 
15. Warrier I, Du W, Natarajan G, Salari V, Aranda J. Patterns of drug utilization in 
a neonatal intensive care unit. J Clin Pharmacol. 2006;46:449-55. 
16. European Medicines Agency. Report on the survey of all paediatric uses of 
medicinal products in Europe [on-line]. 2010 [consultado 2013 Dec 29]. Disponível em: 
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/01/WC5001010
06.pdf  
 Off-label and unlicensed drug use in neonatology: reality in a Portuguese university hospital Dissertação no âmbito do Mestrado Integrado em Medicina, de Joana Raquel Brandão da Silva 
 
17. Anatomical Therapeutic Chemical Code - ATC/DDD Index 2013 [homepage na 
Internet]. WHO Collaborating Centre for Drug Statistics Methodology; 2013 [consultado 
2013 Oct 30]. Disponível em: http://www.whocc.no/atc_ddd_index/. 
18. Infomed - base de dados de medicamentos de uso humano [homepage na 
Internet]. INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde IP; 
2013. [consultado 2013 Oct 30]. Disponível em: 
http://www.infarmed.pt/infomed/pesquisa.php. 
19. Nguyen KA, Claris O, Kassai B. Unlicensed and off-label drug use in a neonatal 
unit in France. Acta Paediatr. 2011;100:615-7. 
20. Oguz SK, HG. Dilmen, U. Off-label and unlicensed drug use in neonatal 
intensive care units in Turkey: the old-inn study. Int J Clin Pharm. 2012;34:136-41. 
21. Laforgia N, Nuccio MM, Schettini F, Dell'aera M, Gasbarro AR, Dell'erba A, et 
al. Off-label and unlicensed drug use among neonatal intensive care units (NICUs) in 
Southern Italy. Pediatr Int. 2013. [Epub ahead of print] 
22. Lass J, Kaar R, Jogi K, Varendi H, Metsvaht T, Lutsar I. Drug utilisation pattern 
and off-label use of medicines in Estonian neonatal units. Eur J Clin Pharmacol. 
2011;67:1263-71. 
23. Khdour MR, Hallak HO, Alayasa KS, AlShahed QN, Hawwa AF, McElnay JC. 
Extent and nature of unlicensed and off-label medicine use in hospitalised children in 
Palestine. Int J Clin Pharm. 2011;33:650-5. 
24. Dell'Aera M, Gasbarro AR, Padovano M, Laforgia N, Capodiferro D, Solarino B, 
et al. Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm 
World Sci. 2007;29:361-7. 
25. Dessi A, Salemi C, Fanos V, Cuzzolin L. Drug treatments in a neonatal setting: 
focus on the off-label use in the first month of life. Pharm World Sci. 2010;32:120-4. 
26. Porta A, Esposito S, Menson E, Spyridis N, Tsolia M, Sharland M, et al. Off-
label antibiotic use in children in three European countries. Eur J Clin Pharmacol. 
2010;66:919-27. 
27. Taketomo CK, Hodding JH, DM. K. Pediatric & Neonatal Dosage Handbook: A 
Comprehensive Resource for all Clinicians Treating Pediatric and Neonatal Patients 
(Pediatric Dosage Handbook). 19th edition ed: Lexi Comp; 2012. 
28. List of paediatric needs [homepage na Internet]. European Medicines Agency; 
2013 [consultado 2013 Oct 30]. Disponível em: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/docu
ment_listing_000096.jsp&mid=WC0b01ac05800260a1. 
29. Ferreira LA, Ibiapina CC, Machado MG, Fagundes ED. High prevalence of off-
label and unlicensed drug prescribing in a Brazilian intensive care unit. Rev Assoc Med 
Bras. 2012;58:82-7. 
30. Bensouda-Grimaldi L, Sarraf N, Doisy F, Jonville-Bera AP, Pivette J, Autret-
Leca E. Prescription of drugs contraindicated in children: a national community survey. 
Eur J Clin Pharmacol. 2007;63:99-101. 
31.      INFARMED - Gabinete Jurídico e Contencioso.  Legislação  Farmacêutica  
Compilada  -  Despacho n.º 18694/2010 [on-line]. 2010 [consultado 2013 Dec 29]. 
Disponível em: 
http://www.infarmed.pt/portal/page/portal/INFARMED/legislacao/legislacao_farmaceuti
ca_compilada/titulo_iii/titulo_iii_capitulo_ii/067-A01_Desp_18694_2010doc.pdf.  
32. Conroy S, McIntyre J. The use of unlicensed and off-label medicines in the 
neonate. Semin Fetal Neonatal Med. 2005;10:115-22. 
 Off-label and unlicensed drug use in neonatology: reality in a Portuguese university hospital Dissertação no âmbito do Mestrado Integrado em Medicina, de Joana Raquel Brandão da Silva 
 
33. Conroy S. Association between licence status and medication errors. Arch Dis 
Child. 2011;96:305-6. 
34. European Parlamient and the Council of the European Union. Regulation(EC) 
No 1901/2006 [on-line]. 2006 [consultado 2013 Dec 29]. Disponível em: 
http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. 
35. Rocchi F, Paolucci P, Ceci A, Rossi P. The European paediatric legislation: 
benefits and perspectives. Ital J Pediatr. 2010;36:56. 
36. European Comission. Better Medicines for Children: From Concept to Reality 
[on-line]. 2013 [consultado 2013 Dec 29]. Disponível em: 
http://ec.europa.eu/health/files/paediatrics/2013_com443/paediatric_report-
com(2013)443_en.pdf. 
  
 Off-label and unlicensed drug use in neonatology: reality in a Portuguese university hospital Dissertação no âmbito do Mestrado Integrado em Medicina, de Joana Raquel Brandão da Silva 
 
Tables and Figures 
 
Figure 1 - Decision tree to classify the drugs according to the Marketing Authorization 
and Summary of Product Characteristics. 
 
EMA – European Medicines Agency; GA – Gestational age; MA - Marketing Authorization;  
OL – Off-label; PNA – postnatal age; SPC - Summary of Product Characteristics. 
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Table 1 – Demographic and clinical characteristics of our patients 
 
Total 
n=218 a,b 
Preterm 
n=94c 
Full-term 
n=124 
p value 
Gender, n (%) 
Male 
Female 
 
121 (55.5) 
97 (44.5) 
 
50 (53.2) 
44 (46.8) 
 
71 (57.3) 
53 (42.7) 
 
0.550* 
Gestational age (wk), mean (±SD) 36.07 (±4.0) 32.4(±3.2) 38.9(±1.2) <0.0001
§ 
Birthweight (g), mean (±SD) d 
2554 
(±910.5) 
1765 
(±628.9) 
3152 
(±570.9) 
<0.0001§ 
Delivery, n (%) 
C-section 
Vaginal 
Forceps or vacuum 
 
120 (55) 
71 (32.6) 
27 (12.4) 
 
60 (63.8) 
28 (29.8) 
6 (6.4) 
 
60 (48.4) 
43 (34.7) 
21 (16.9) 
 
 
0.023* 
Apgar score 1st min, n (%) 
0 – 7 
8 – 10 
 
69 (31.8) 
148 (68.2) 
 
30 (31.9) 
64 (68.1) 
 
39 (31.7) 
84 (68.3) 
 
0.974* 
Apgar score 5th min, n (%) 
0 – 7 
8 – 10 
 
33 (15.1) 
185 (84.9) 
 
17 (18.1) 
77 (81.9) 
 
16 (12.9) 
108 (87.1) 
 
0.290* 
Place of birth, n (%) 
Inborn 
Outborn 
 
161 (73.9) 
57 (26.1) 
 
73 (77.7) 
21 (22.3) 
 
88 (71) 
36 (29) 
 
0.265* 
Number of drugs needed, median 
(min-max) 
3 (0-34) 4 (0-34) 2 (0-22) <0.0001
¥ 
Length of stay (days), median 
(min-max) 
7 (1-210) 9 (1-210) 6 (1-90) <0.0001
¥ 
Discharged, n (%) 
Home 
Other hospital 
Other department 
Deceased 
 
131 (60.1) 
43 (19.7) 
36 (16.5) 
8 (3.7) 
 
50 (50.3) 
32 (34) 
6 (6.4) 
6 (6.4) 
 
81 (65.3) 
11 (8.9) 
30 (24.2) 
2 (1.6) 
 
 
<0.0001* 
a 
Three neonates were admitted twice in the NICU; 
b
 Thirty-three neonates were born from a 
twin pregnancy; 
c
 Ten neonates (4.6%) were extremely preterm (<28 weeks), 23 (10.1%) were 
very preterm (28-31 weeks), 61 (28%) were late preterm (32-36 weeks) and 53 (42.7%) were 
full-term; 
d
 Thirty-one patients (14.2%) with very low birth weight (≤ 1500 g); 
*
Chi-square test; 
§ 
Independent t test; 
¥
 Mann-Whitney U test. 
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Table 2 – Active substances prescribed to our patients, listed in descending order of 
frequency of administration 
Approved for neonatal 
period and used 
according to SPC 
Cholecalciferol, Caffeine Citrate, Multivitamins, Clotrimazole, 
Furosemide, Iron(III)-Hydroxide Polymaltose, Dopamine, 
Midazolam, Poractant Alfa, Vancomycin, Cefotaxime, 
Alprostadil, Paracetamol, Epoetin Beta, Ibuprofen, 
Phytomenadione, Iron(III)-Hydroxide Sucrose, Phenobarbital, 
Palivizumab, Atropine, Nystatin, Teicoplanin, Meropenem, 
Milrinone, Flucloxacillin, Naloxone, Alfacalcidol, Digoxin, 
Erythromycin, Hepatitis B Immunoglobulin, Levocarnitine, Nitric 
Oxide 
Approved for neonatal 
period but off-label use 
for gestational age 
Paracetamol, Amikacin, Fluconazole 
 
Approved for neonatal 
period but off-label use 
for indication 
Midazolam 
Approved for neonatal 
period but off-label use 
for route of 
administration 
Calcium Polystyrene Sulphonate 
Approved for neonatal 
period but off-label use 
for dose and/or 
frequency 
Gentamicin, Ampicillin, Paracetamol, Amikacin, Vancomycin, 
Metronidazole, Phenobarbital, Cefotaxime, Teicoplanin, 
Milrinone, Fluconazole 
Off-label for neonatal 
period 
Domperidone, Ranitidine, Sodium Bicarbonate, Cefazolin, 
Fentanyl, Salbutamol, Budesonide, Human Immunoglobulin G, 
Aciclovir, Ipratropium Bromide, Levetiracetam, Adenosine, 
Amphotericin B, Cefaclor, Flumazenil, Isoprenaline, 
Levosimendan, Lysine Acetylsalicylate, Ofloxacin, 
Phenylephrine 
Undetermined approval 
state for neonates 
Dexamethasone, Epinephrine , Tropicamide, Dobutamine, 
Gentamicin (ophtalmic), Fusidic Acid, Human Albumin, 
Hydrocortisone, Norepinephrine, Oxytetracycline 
Contraindicated for 
neonates 
Morphine, Chloramphenicol, Phenylephrine (ophtalmic), 
Miconazole, Rifamycin 
Unlicensed Trimethoprim, Chloral Hydrate, Propranolol, Spironolactone, 
Acetylsalicylic Acid, Ursodeoxycholic Acid, Calcium Carbonate, 
Flecainide, Hydrochlorothiazide, Captopril, Folic Acid, 
Omeprazole 
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Figure 2 – The distribution of drugs administered according to the Anatomical 
Therapeutic Chemical Classification system (n=1011 prescriptions) 
 
A - Alimentary tract and metabolism;  B - Blood and blood forming organs; C - Cardiovascular 
system; D – Dermatological; H - Systemic hormonal preparations; J - Anti-infective for systemic 
use; N - Nervous system; R - Respiratory system; S - Sensory organs; V- Various. 
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Table 3 – Approved drugs for neonatal period (n=716) and non-approved approved 
drugs for neonatal period (n=295) 
 
Total 
(n=1011) 
Pre-term 
(n=596) 
Full-Term 
(n=415) 
p value 
Approved for neonatal period, n (%) 
716 
(70.8) 
433 
(72.6) 
283 
(68.2) 
0.125§ 
Drugs used according to SPC, n (%)  
434 
(42.9) 
294 
(49.3) 
140 
(33.7) 
<0.0001
*
 
 
Off-label for GA, n (%)   
2 
(0.2) 
2 
(0.3) 
0 0.521
§
 
Off-label for indication, n (%)   
4 
(0.4) 
1 
(0.2) 
3 
(0.7) 
0.306
§
 
Off-label for route of administration, n (%) 
2 
(0.2) 
1 
(0.2) 
1 
(0.3) 
0.762
§
 
Off-label for dose and/or frequency, n (%) 
260 
(25.7) 
121 
(20.3) 
139 
(33.5) 
<0.0001
*
 
 
Off-label for GA and for dose, n (%) 
14 
(1.4) 
14 
(2.3) 
0 0.001
§
 
 
Non-approved for neonatal period, n (%) 
295 
(29.2) 
163 
(27.4) 
132 
(31.8) 
0.125§ 
Off-label for neonatal period, n (%) 
102 
(10.1) 
63 
(10.6) 
39 
(9.4) 
0.542
§
 
Undetermined approval state for neonates, n(%) 
61 
(6.0) 
37 
(6.2) 
24 
(5.8) 
0.780
§
 
Contra-indicated for neonates, n (%) 
88 
(8.7) 
41 
(6.9) 
47 
(11.3) 
0.012
§
 
Unlicensed, n (%) 
44 
(4.4) 
22 
(3.7) 
22 
(5.3) 
0.217
§
 
 
GA-Gestational age; 
*
Chi-square test; 
§ 
Fisher’s exact test. 
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Table 4 – Drugs by route of administration 
 
Total of 
prescriptions 
n=1011 
Preterms 
 
n=596 
Full-terms 
 
n=415 
p value 
Intravenous, n (%) 
622 
(61.4) 
329 
(55.2) 
293 
(70.6) 
<0.0001* 
Oral, n (%) 
217 
(21.5) 
147 
(24.7) 
70 
(16.9) 
0.003* 
Ophtalmic, n (%) 
56 
(5.5) 
38 
(6.4) 
18 
(4.3) 
0.163* 
Transdermal, n (%) 
40 
(4.0) 
25 
(4.2) 
15 
(3.7) 
0.642* 
Endotracheal, n (%) 
25 
(2.5) 
22 
(3.7) 
3 
(0.7) 
0.003§ 
Inhalation, n (%) 
11 
(1.1) 
8 
(1.3) 
3 
(0.7) 
0.382§ 
Subcutaneous, n (%) 
10 
(1.0) 
10 
(1.7) 
0 0.007
§ 
Intramuscular, n (%) 
6 
(0.6) 
4 
(0.7) 
2 
(0.5) 
0.700§ 
Buccal, n (%) 
4 
(0.4) 
1 
(0.2) 
3 
(0.7) 
0.311§ 
Instillationa, n (%) 
1 
(0.1) 
1 
(0.2) 
0 0.404§ 
Nasal, n (%) 
1 
(0.1) 
0 
1 
(0.2) 
0.410§ 
Two or more, n (%) 
 
18 
(1.8) 
11 
(1.7) 
7 
(1.7) 
0.815* 
a Instillation in a nephrostomy; *Chi-square test; § Fisher’s exact test  
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1. AIMS
 the aim of Acta Médica Portuguesa is to publish origi-
nal research and review articles in biomedical areas of the 
highest standard, covering several domains of medical 
knowledge, with the purpose to help doctors improve medi-
cal care.
 in order to accomplish these aims, Acta Médica Portu-
guesa publishes original articles, review articles, case re-
ports and editorials, among others, with a focus on clinical, 
scientific, social, political and economic factors affecting 
health. Acta Médica Portuguesa will be happy to consider 
manuscripts for publication from authors anywhere in the 
world.
2. VALUES
 Our principles are to promote:
 scientific quality.
 Knowledge and state of the art scientific expertise.
 editorial independence and impartiality.
 ethics and respect for human dignity.
 social responsibility.
3. PERSPECTIVES
 to be acknowledged as a Portuguese medical journal 
with a relevant international impact.
 to promote a scientific publication of the highest quality, 
giving priority to original research work in the field of clinical, 
epidemiological, multicentric studies and basic science.
 to remain a publication forum of guidelines.
 to enhance international dissemination.
 Our motto “Primum non nocere, Acta Médica Portugue-
sa in the first place”.
4. GENERAL INFORMATION
 Acta Médica Portuguesa is the Portuguese Medical As-
sociation (Ordem dos Médicos) scientific journal with peer 
review.
 it has been published continuously since 1979, being in-
dexed in PubMed / Medline from the first issue. since 2010 
it has an impact Factor attributed by the Journal Citation 
Reports - thomson Reuters.
 Acta Médica Portuguesa follows a free access policy. 
All manuscripts are available in full, in an open and free 
form since 1999 at www.actamedicaportuguesa.com and 
through Medline with a PubMed interface.
 the rate of acceptance of Acta Médica Portuguesa is 
approximately 55% of the more than 300 annually received 
manuscripts.
 the manuscript must be submitted online through
“Online submissions / Submissões Online” at http://www.
actamedicaportuguesa.com/revista/index.php/amp/about/
submissions#onlinesubmissions.
 Acta Médica Portuguesa follows the good practice 
guidelines of the biomedical edition of the international 
Committee of Medical Journal editors (iCMJe), the Com-
mittee on Publication ethics (COPe) and the eQuAtOR 
Network Resource Centre guidance on good Research 
Report (study design).
 Our publication editorial policy inserts in the revision 
and publication process the  Recommendations of editorial 
Policy (editorial Policy statements) issued by the Council 
of science editors, available in http://www.councilscien-
ceeditors.org/i4a/pages/index.cfm?pageid=3331, covering 
responsibilities and rights of the editors of publications with 
scientific peer review.
 the proposed manuscript should not have been object 
of any other kind of publication. the views expressed are 
those of the Author(s). the published manuscript will re-
main a joint ownership of the Acta Médica Portuguesa and 
of the Author(s).
 The Acta Médica Portuguesa reserves the marketing 
right of the manuscript as an integral part of the journal (for 
instance, for reprint purposes). the Author(s) should add to 
the submission letter a copyright declaration for commercial 
purposes.
 Regarding the use by third parties, the Acta Médica Por-
tuguesa is governed by the license Creative Commons ‘At-
tribution – Noncommercial - Noderivatives (by-nc-nd)’.
 After publication in Acta Médica Portuguesa, the Authors 
are free to provide their manuscripts to their original institu-
tions, as long as publication in Acta Médica Portuguesa is 
acknowledged.
5. AUTHORSHIP CRITERIA
 the journal follows the authorship criteria of the “inter-
national Committee of Medical Journal editors” (iCMJe).
 in order to be designated as an Author, there should be 
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significant participation in the work, so that the Author must 
assume responsibility for its content and authorship credits.
 An Author is someone:
 1. Having had a substantial and direct intellectual contri-
bution on the design and preparation of the manuscript
 2. Having participated in data analysis and interpretation
 3. Having participated in the writing of the manuscript, 
making a revision of the drafts; critical content review or ap-
proval of the final version
 Conditions 1, 2 and 3 have to be met.
 Authorship requires a substantial contribution to the 
manuscript. it is required that the contribution of each Au-
thor to the work is specified in a presentation letter.
 Being listed as an Author, while not meeting eligibility 
criteria is considered as a fraud.
 everyone who has contributed to the manuscript, but 
who does not meet the authorship criteria, should be re-
ferred in the acknowledgements.
 every Author (i.e. the Corresponding Author and each 
of the Authors) has to fill and sign the “Authorship Form” 
with the authorship responsibility, criteria and contributions; 
conflicts of interest and sponsorship, including the Authors’ 
copyright transfer.
 the Corresponding Author should be the intermediary, 
on behalf of all the co-authors, in all contacts with Acta Mé-
dica Portuguesa during the whole process of submission 
and revision. the Corresponding Author is responsible for 
ensuring that any potential conflict of interest is correctly 
referred. the Corresponding Author should also testify, on 
behalf of all the co-authors, the originality of the work and 
obtain the written authorization of each person mentioned in 
the section “Acknowledgments”.
6. COPYRIGHT / AUTHORSHIP RIGHTS
 When the manuscript is accepted for publication, it is re-
quired that the digitalized document is sent by email, signed 
by all the Authors, together with the Author’s copyright 
transfer between the Authors and Acta Médica Portuguesa.
the Author(s) should sign one copy of the copyright transfer 
document between the Author(s) and Acta Médica Portu-
guesa when the manuscript is submitted:
Note: this signed document should only be sent when the 
manuscript has been accepted for publication.
editor of Acta Médica Portuguesa
the Author(s) certify that the manuscript entitled (see form 
below): ________________________________________
____ (ref. AMP________) is original, that all the statements 
presented as facts are based on research of the Author(s) 
and the manuscript in part or in whole does not violate any 
copyright rules. in addition, the manuscript does not violate 
any privacy right, has not been published partially or totally, 
has not been submitted for publication, in whole or in part, 
in any other journal and the Author(s) has the right to the 
copyright.
 All Authors further declare that they have participated 
in the work, that it is their responsibility and that there are 
no conflicts of interest, regarding any of the Authors, in the 
statements issued in the work.
 the Authors, when submitting the work for publication, 
share with Acta Médica Portuguesa all the rights and 
interests of the manuscript copyright.
All the Authors must sign
date:__________________________________________
Name (capital letters):______________________________
signature:_______________________________________
7. CONFLICTS OF INTEREST
 the content accuracy, as well as the opinions ex-
pressed are an exclusive responsibility of the Author(s). the 
Author(s) must declare every potential conflict of interest. 
 the Author(s) must declare all financial and personal 
relations that may bias the work.
 in order to prevent any ambiguity, the Author(s) must 
explicitly declare if there are or there are not any conflicts of 
interest.
 this information should not influence the editorial de-
cision but, before submitting the manuscript, the Author(s) 
must guarantee any necessary authorization for the publi-
cation of the submitted material.
 if in doubt about the meaning of a relevant financial or 
personal interest, the Author(s) should contact the editor.
8. INFORMED CONSENT and ETHICS APPROVAL
 Any patient (or legal representative) that may be iden-
tified in a written description, photo or video, should sign 
an informed consent form allowing for these descriptions. 
these documents should be submitted with the manuscript.
 The Acta Médica Portuguesa considers that it is accept-
able to omit data or utilize less specific data presentation 
in the identification of a patient. Nevertheless, further data 
alterations will not be acceptable.
 the Authors should inform if the work has been ap-
proved by their institution’s ethics Committee, according to 
the Helsinki declaration.
9. LANGUAGE
 Manuscripts should be written in Portuguese or in eng-
lish. titles and abstracts must always be written in Portu-
guese and in english.
10. EDITORIAL PROCESS
 the Corresponding Author will be notified by email re-
garding the reception of the manuscript and any editorial 
decision.
 All submitted manuscripts are initially reviewed by the 
editor of Acta Médica Portuguesa. the manuscripts will be 
assessed under the following criteria: 
originality, relevance, clarity, appropriate study method, 
valid data, adequate and data supported conclusions, im-
portance, meaningful and scientific contribution to a specific 
area. the manuscript should not have been published, in 
whole or in part, nor submitted for publication elsewhere. 
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 The Acta Médica Portuguesa follows a strict single-
blind peer-review process. experts in the relevant area of 
the manuscript will be requested to draw their comments, 
including acceptance suggestion, conditioned acceptance 
to minor or important modifications, or rejection. in this as-
sessment process, the manuscript may be: 
 a) accepted without any modifications; 
 b) accepted after modifications suggested by the scien-
tific advisors; 
 c) rejected.
 the following schedule is established in this process:
 • After receiving the manuscript, the editor-in-Chief, or 
one of the Associate editors will send the manuscript to 
at least two reviewers, assuming that it meets publication 
rules and editorial policy. it may be rejected at this stage, 
without being sent to reviewers.
 • When receiving the acceptance communication, the 
Authors should immediately email the copyright transfer 
form found at the site of Acta Médica Portuguesa, complet-
ed and signed by all Authors.
 • the reviewer will be asked to answer the editor in a 
maximum of four weeks, stating his comments on the man-
uscript under revision, including his suggestion regarding 
the acceptance or rejection of the work. Within a period of 
two weeks, the editorial Council will take a first decision 
which may entail acceptance with no further modifications, 
may include reviewers comments so the Authors may pro-
ceed according to what is indicated or may indicate manu-
script rejection. 
 Authors will have a period of 20 days to submit a new 
written version of the manuscript, addressing the modifica-
tions suggested by the reviewers and by the editorial Coun-
cil. When any modification is proposed, the Authors should 
email the editor, in a maximal period of twenty days, with 
all the requested answers in addition to a written version of 
the manuscript with the inserted modifications in a different 
colour.
 • the editor-in-Chief will have a period of 15 days to 
reach a decision about the new version: rejecting or accept-
ing the manuscript in its new version or submitting to one 
or more external reviewers whose opinion may or may not 
meet the first revision.
 • in case the manuscript has to be re-sent for an exter-
nal revision, the experts will have a period of four weeks 
to send their comments and their suggestion regarding the 
acceptance or rejection for publication.
 • According to the suggestions of the reviewers, the 
editor-in-Chief may accept the manuscript in this new ver-
sion, may reject or ask for modifications once again. in the 
latter case, the Authors shall have a period of one month to 
submit a reviewed version, which may, in case the editor-in-
Chief so determines, be subjected to another revision pro-
cess by external experts.
 • in case of being accepted, in any of the referred stag-
es, the decision will be sent to the Corresponding Author. 
in a period of less than one month, the editorial Council 
will send the manuscript for revision by the Authors with the 
final format, not including citation details. the Authors will 
have a period of five days for the text revision and to com-
municate any typographical error. At this stage, the Authors 
are not allowed to do any relevant modification, beyond any 
corrections of minor typographical and/or spelling mistakes. 
data changes in graphs, tables or text, etc., are not allowed.
 • After the Authors provide an answer, or if there has 
been no answer, the manuscript is considered completed, 
after the above-mentioned five day period.
 • At the revision stage of proofreading, any relevant 
change in the manuscript will not be accepted and may 
mean further rejection by decision of the editor-in-Chief. 
 Any transcription of images, tables or charts from other 
publications must meet prior authorization by the original 
authors, meeting copyright rules.
11. FAST-TRACK PUBLICATION
 Fast-track publication system is available in Acta Mé-
dica Portuguesa for urgent and important manuscripts that 
meet the Acta Médica Portuguesa requirements for the 
Fast-track system. 
 a) Authors may apply for a fast-track publication through 
manuscript submission at http://www.actamedicaportugue-
sa.com/ under the heading “submit manuscript / submeter 
artigo”, clearly indicating why the manuscript should be con-
sidered for fast publication. 
 the editorial Review Board will then take the decision 
as regards the suitability of the request for fast (Fast-track) 
or otherwise regular publication.
 b) Authors must verify that the manuscript meets the 
rules that apply for submission and contains the complete 
information required by Acta Médica Portuguesa.
 c) the editorial Review Board will communicate their 
decision within a 48 hour period, if the manuscript is con-
sidered appropriate for fast-track publication. if the editor-
in-Chief finds the manuscript unsuitable for Fast-track 
evaluation, the manuscript may be proposed for the normal 
revision process, in which case Author(s) will be allowed to 
withdraw their submission.
 d) For manuscripts that are accepted for Fast-track 
evaluation, an editorial decision will be made available 
within five working days.
 e) if the manuscript is accepted for publication, an effort 
will be made to publish online within a maximal period of 
three weeks after acceptance.
 
12. THE GOLDEN RULES OF ACTA MéDICA PORTU-
GUESA
 a) the editor will be responsible for maintaining quality, 
ethics, relevance and the up-to-date content of the journal.
 b) Any complaint will be dealt with by the editor-in-Chief 
and not by the President of the Portuguese general Medical 
Council (Ordem dos Médicos).
 c) Peer review must engage an external reviewers’ eva-
luation.
 d) upon manuscript submission, confidentiality will be 
ensured by the editors and by all persons involved in peer-
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 e) Reviewers’ identity will remain confidential.
 f) the reviewers advise and formulate recommenda-
tions; the editor is responsible for the final decision.
 g) the editor-in-Chief has full editorial independence.
 h) the Portuguese general Medical Council does not 
directly interfere with evaluation, selection or edition of spe-
cific manuscripts, nor directly or indirectly in editorial deci-
sions.
 i) editorial decisions are based on the merit of the sub-
mitted manuscript and journal interests.
 j) editor-in-Chief decisions are not influenced by the 
manuscript’s origin nor are they determined by any external 
agents.
 k) Reasons for immediate rejection without any external 
peer review include: lack of originality; limited interest for 
Acta Médica Portuguesa’ readers; serious methodological 
or scientific errors; superficial overview of a specific topic; 
excess of preliminary and/or descriptive data; outdated in-
formation.
 l) All peer-review elements should act according to the 
highest ethical patterns.
 m) All peer-reviewers must declare any potential conflict 
of interest and ask to be excluded from manuscript review 
whenever any doubt arises regarding the possibility of bias 
or incapacity for an objective review.
13. GENERAL RULES
STYLE
 All manuscripts must be prepared in accordance with 
the “AMA Manual of style”, 10th ed. and/or “uniform Re-
quirements for Manuscripts submitted to Biomedical Jour-
nals”. 
 You are advised to write in a clear, direct and active 
style. in general, the first person should be used, in the ac-
tive voice. As an example, write “We analyzed data” and not 
“data was analyzed”. Acknowledgements are an exception 
to this guidance as they should be written using the third 
person and in the active voice, as exemplified by: “the au-
thors would like to thank…..”. Latin words or in a language 
other than the one written in the text should be in italic.  the 
components of the manuscript are: title Page, Abstract, 
text, References and, if appropriate, figure legends. each 
different section should be started on a new page, consecu-
tively numbered from the title Page. Manuscripts should be 
saved in Word or WordPerfect. do not submit in PdF for-
mat. 
SUBMISSION
 Manuscripts must be submitted online, via the “Online 
submission / Submissão Online” section of  Acta Médica 
Portuguesa http://www.actamedicaportuguesa.com/revista/
index.php/amp/about/submissions#onlinesubmissions.
 Answers to every single field in the online submission 
form must be provided. Confirmation of manuscript submis-
sion will be received by the Author(s) together with a code 
number that will be attributed to the manuscript.
 Mention in the first page/title page:
 a) title in Portuguese and in english – concise and 
descriptive
 b) Names of all Authors (first and last name) together 
with academic and/or professional titles and affiliation 
(department, institution, city and country).
 c) subsidies or grants that contributed to the work.
 d) Address and email of the Corresponding Author. 
 e) Brief title for a heading. 
Mention in the second page  
 a) title (no authors)
 b) Abstract in Portuguese and in english. the abstract 
may only contain information described in the manuscript. 
Abstracts must not cite the text or figures/tables of the man-
uscript. 
 c) Keywords. After the abstract, a maximum number of 
5 keywords written in english must be provided, using the 
recommended nomenclature in Medical subject Headings 
(MesH), http://www.nlm.nih.gov/mesh/MBrowser.html
Mention in the third and following pages:
 Editorials
 editorials are only to be submitted upon invitation by the 
editor of Acta Médica Portuguesa and will concern currently 
relevant topics. Authors will be asked not to exceed 1200 
words, not to include tables or figures and to use a maxi-
mum of 5 references. An abstract is not required. 
 
 Current Perspective: 
 this is the type of manuscript that is submitted upon 
invitation by the editorial Board. it may cover a broad diver-
sity of themes focusing on health care: current or emergent 
problems, management and health policies, history of medi-
cine, society issues and epidemiology, among others. An 
Author that wishes to propose a manuscript in this section is 
requested to send an abstract to the editor-in-Chief includ-
ing the title and Author list for evaluation. A maximum num-
ber of words is 1200 (excluding references and legends), 
up to 10 references, one table or one figure are allowed. An 
abstract is not required.  
 Original Manuscripts: 
 text must be divided in sections as follows: introduc-
tion (including Objectives), Material and Methods, Results, 
discussion, Conclusions, Acknowledgments (if applicable), 
References, tables and Figures. 
 Original Manuscripts must not exceed 4000 words, ex-
cluding references and illustrations. it must be accompa-
nied by illustrations with a maximum of 6 figures/tables and 
a maximal number of 60 references. the abstract should 
not exceed 250 words and must be structured as follows: 
introduction; Material and Methods, Results, discussion 
and Conclusion. 
 As a member of iCMJe, Acta Médica Portuguesa re-
quires that all trials be registered in a public trial registry 
which is accepted by the iCMJe, in order for manuscript 
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publication (in other words, the registry must be a non lu-
crative institution which is publicly accessible, for example: 
www.clinicaltrials.gov). 
 All manuscripts that report clinical trials must follow the 
CONsORt Statement (http://www.consort-statement.org/). 
 A systematic review or meta-analysis must follow the 
PRisMA guidelines. in the case of a meta-analysis of ob-
servational studies the MOOse guidelines must be fol-
lowed and the study protocol should be presented as a sup-
plementary file. stARd guidelines must be followed in the 
case of a study of diagnostic accuracy and the stROBe 
guidelines in observational studies. in Clinical guidelines 
we encourage the Author to follow the gRAde guidance for 
evidence classification.
 
 Review Manuscripts:
 these are destined to thoroughly approach state of the 
art knowledge with respect to important themes. these 
manuscripts will usually be elaborated by invitation from the 
editorial team; however, in exceptional circumstances, it 
will be possible for experts in the field to submit to the jour-
nal a project regarding a review article. in the latter case, 
those projects that are judged to be relevant and are, as 
such, approved by the editor, may then be developed and 
submitted according to the publication rules. the text must 
not exceed 3500 words (not including the abstract, legends 
and references). A maximum of 4 tables and/or figures and 
no more than 75 references are allowed. the abstract must 
not exceed 250 words and must be structured as follows: 
introduction; Material and Methods, Results, discussion 
and Conclusion.  
 Case Report
 Report of a clinical case should be justified by its rar-
ity, unusual aspects, atypical progress, diagnostic or thera-
peutic innovation, among others. the sections should be 
as follows: introduction, Case report, discussion and Refer-
ences. the text must not exceed 1000 words and no more 
than 15 references are allowed. it should be accompanied 
by illustrative figures. the number of tables and figures 
must not exceed 5. A non-structured abstract not exceeding 
150 words, summarizing the objective, main messages and 
conclusions must accompany submission. 
 Images in Medicine (Medical Image) 
  images in Medicine is an important contribution for the 
apprenticeship and practice of medicine. the type of medi-
cal images that are suitable include clinical images, imaging 
techniques, histopathology and surgery. up to two images 
per case are accepted. this modality allows for a title with a 
maximum of eight words and a text with a maximum of 150 
words referring to relevant clinical information and includ-
ing a brief summary of the patients history, laboratory data, 
treatment and current clinical situation. No more than three 
authors and five references are allowed and an abstract is 
not required. Only original high quality photographs are ac-
cepted for publication which must be original. two different 
files are requested: one must contain the photograph in the 
high quality required for publication and another which is 
meant to be used as reference, where the top of the pho-
tograph must be indicated with an arrow. information about 
submission of digital images is available at “technical rules 
for figures, tables or photographs submission / Normas téc-
nicas para a submissão de figuras, tabelas ou fotografias”. 
 Guidelines: 
 Medical societies, medical colleges, official entities and/
or groups of physicians wishing to publish Clinical Practice 
guidelines in Acta Médica Portuguesa must previously con-
tact the editorial Council and submit the complete text in 
a version prepared for publication. the editor-in-Chief may 
condition publication in Acta Médica Portuguesa to an ex-
clusivity agreement. it may be possible to publish a sum-
marized version in the printed edition together with the com-
plete publication of the version in the internet site of Acta 
Médica Portuguesa. 
 Letters to the Editor: 
 A Letter to the editor must consist of a comment regard-
ing an article published in the Acta Med Port or a short state-
ment regarding a clinical subject or case study. it should not 
exceed 400 words, should not include more than one figure 
and a maximum of 5 references are allowed.  An abstract is 
not required.
 the general structure should be as follows: identifica-
tion of the article (indicated as reference 1); the reason to 
write the letter; evidence based statements (from the litera-
ture or from personal experience); a summary and literature 
references must be provided.
 the answer(s) of the Author(s) should keep the same 
format.
 A Letter to the editor discussing a recently published 
Acta Med Port article has the highest acceptance probabi-
lity if submitted within four weeks of the article publication
Abbreviations: do not use abbreviations or acronyms nei-
ther in the title nor in the summary and limit their use in 
the text. the use of acronyms must be altogether avoided 
as well as the excessive and unnecessary use of abbrevia-
tions. if the use of uncommon abbreviations is found to be 
absolutely required, when first utilized they must be ade-
quately defined, in full, and immediately followed by the said 
abbreviation in parenthesis. do not follow abbreviations by 
full stops.  
Measurement Units: units of length, height, weight and 
volume must be expressed in the metric system units (me-
tre, kilogram or litre) and their decimal units. temperatures 
must be presented in Celsius degrees (ºC) and blood pres-
sure in millimetres of mercury (mmHg). For more informa-
tion please consult the conversion table “units of Measure” 
provided at the website of AMA Manual of style (http://www.
amamanualofstyle.com/) 
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Names of Drugs, Devices or other Products:  use the 
non-commercial name of drugs, devices or other products 
unless the commercial name is essential for discussion.
IMAGES 
 enumerate all images (figures, graphs, tables, photo-
graphs, illustrations) by text citation order. include a title/
legend for each image (a brief sentence, preferably not ex-
ceeding 15 words). Colour images will be published at no 
extra charge. the following formats are acceptable in the 
manuscript:  
 BMP, ePs, JPg, PdF and tiF. these should have a 
300 dpi resolution and be at least 1200 pixels wide and in 
proportion to height. 
 tables and Figures must be enumerated by text citation 
order by Arabic numbers and identified as Figure/table. An 
Arabic number as well as a legend must be attributed to 
tables and Figures. each Figure/table must be referenced 
in the text as exemplified as follows: “these are some ex-
amples of an abnormal immune response that may be at 
the origin of Behçet´s disease. (Fig. 4). this is associated 
with two other cutaneous lesions (table 1).”
 When a Figure is mentioned in the text it should be ab-
breviated to Fig. while the word table should not be abbrevi-
ated. in legends, both words must be written in full. Figures 
and tables should be enumerated with Arabic numbers in-
dependently and according to the sequence with which they 
are cited in the text. example: Fig. 1, Fig. 2, table 1. 
Legends: After the reference section, a detailed legend (no 
abbreviations) must be included with each image in the file 
with the text manuscript. the image must be referenced in 
the text and its approximate location must be indicated “in-
sert Figure 1……here”.
Tables: it is compulsory to send tables in black and white at 
the end of the file. tables must be presented and submitted 
in a word document, in a simple table format (simple grid), 
without tabs or other typographical formats.  All tables must 
be mentioned in the text of the manuscript and enumerated 
in the order mentioned in the text. indicate the respective 
approximate location in the body of the manuscript with the 
comment “insert table 1… here”. Authors must be prepared 
to authorize the reorganization of tables as considered 
necessary. tables must be accompanied by the respective 
legend/title which must be elaborated in a brief and clear 
form. Legends must be self-explanatory (without the need 
to refer to the text of the manuscript) – written as a descrip-
tive statement. 
Legends/Titles of Tables: Place these at the top of the 
table, justified to the left. tables are read top-down. All infor-
mation should be placed in the inferior portion of the table 
– end of page notes (abbreviations, statistical significance, 
etc.). end of page notes that are too extensive for the title 
or data cells must use the following symbols *, †, ‡, §, ||, ¶, 
**, ††, ‡‡, §§, ||||, ¶¶.
Figures: Authors may use as many files as required, each 
pertaining to a Figure and submitted separately, in an elec-
tronic version and ready for publication. A word file is unsuit-
able and will not be accepted for Figure submission, includ-
ing photographies, drawings and graphs. these should be 
submitted in format tiF, JPg, BMP, ePs and PdF with a 
300 dpi resolution, at least 1200 pixels wide and in propor-
tion to height. Legends must be placed in the file pertaining 
to the manuscript text. if the figure is copyrighted material 
it is the responsibility of the Author(s) to obtain the relevant 
legal permission before sending the file to Acta Médica Por-
tuguesa. 
Figure Legend: these are placed underneath the figure 
or graph and justified to the left. graphs and other figures 
are usually read bottom up. images of patients are only 
accepted if judged necessary for the understanding of the 
manuscript. if the patient can be identified in the figure then 
patient authorization for publication must be obtained and 
sent to Acta Médica Portuguesa. if the photograph allows 
for very obvious patient recognition then it may be found to 
be unsuitable for publication and, in case of doubt, the final 
decision will rest with the editor-in-Chief. 
•	 Photographs: in format tiF, JPg, BMP and PdF with 
a 300 dpi resolution and at least 1200 pixels wide and in 
proportion to height. 
•	 Drawings and graphs: drawings and graphs must be 
sent in a vector format (Ai, ePs) or in a bitmap file with a 
minimal resolution of 600 dpi. drawings and graphs must 
be in Arial letter font. images must be presented in separate 
files, submitted as supplementary documents, in conditions 
of reproduction and according to the order in which they are 
discussed in the text. images must be submitted indepen-
dently of the text. 
ACKNOWLEDGMENTS (optional)
 these must be placed after the text and must address 
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